**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Jonathan Hu, Queen's Medical Center, Honolulu, HI

**Main Body of the Abstract**
Introduction: Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that disproportionately affects African Americans in the United States. Hereditary transthyretin CA clusters by race and geography worldwide but few studies have evaluated epidemiological trends in Asian and Native Hawaiian or Pacific Islander (NHOPI) populations. We sought to determine the demographics of CA in Hawaii’s majority-minority population.
Methods: This is a retrospective cross-sectional study of patients diagnosed with CA between January 2019 and December 2023 at a tertiary cardiovascular center in Hawaii. Serum and urine protein electrophoresis, free light chains and immunofixation, and bone scintigraphy were utilized to differentiate between transthyretin (ATTR) and light chain amyloidosis (AL)
Results: A total 64 patients (34.4% Whites, 45.3% Asians, 15.6% NHOPI,  4.7% Blacks) were diagnosed with CA with an average age of 78.4±10.1 years. Of that, 46 (71.9%) were male, 58 (90.6%) had ATTR, and six (9.4%) had AL. Nine NHOPI patients had ATTR without genetic mutations. Amongst Asians, 25 had ATTR and one Japanese patient had a V50M mutation. 21 white patients had ATTR without genetic mutations. Two Black patients had ATTR amyloidosis and both had the V142I mutation. Three ATTR patients and one AL patient received heart and bone marrow transplant.
Conclusion: This study is one of the first to evaluate CA demographics amongst Hawaii’s majority-minority population. Although our data for White and Black patients follow national trends, no mutations were identified in NHOPI’s. Larger studies are needed to evaluate the disease burden of hereditary ATTR amongst NHOPI and Asian patients in Hawaii.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Jonathan Hu, Queen's Medical Center, Honolulu, HI

**Main Body of the Abstract**
**Introduction:** Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy that disproportionately affects African Americans in the United States. Hereditary transthyretin CA clusters by race and geography worldwide but few studies have evaluated epidemiological trends in Asian and Native Hawaiian or Pacific Islander (NHOPI) populations. We sought to determine the demographics of CA in Hawaii’s majority-minority population.
**Methods:** This is a retrospective cross-sectional study of patients diagnosed with CA between January 2019 and December 2023 at a tertiary cardiovascular center in Hawaii. Serum and urine protein electrophoresis, free light chains and immunofixation, and bone scintigraphy were utilized to differentiate between transthyretin (ATTR) and light chain amyloidosis (AL)
**Results:** A total 64 patients (34.4% Whites, 45.3% Asians, 15.6% NHOPI,  4.7% Blacks) were diagnosed with CA with an average age of 78.4±10.1 years. Of that, 46 (71.9%) were male, 58 (90.6%) had ATTR, and six (9.4%) had AL. Nine NHOPI patients had ATTR without genetic mutations. Amongst Asians, 25 had ATTR and one Japanese patient had a V50M mutation. 21 white patients had ATTR without genetic mutations. Two Black patients had ATTR amyloidosis and both had the V142I mutation. Three ATTR patients and one AL patient received heart and bone marrow transplant.
**Conclusion:** This study is one of the first to evaluate CA demographics amongst Hawaii’s majority-minority population. Although our data for White and Black patients follow national trends, no mutations were identified in NHOPI’s. Larger studies are needed to evaluate the disease burden of hereditary ATTR amongst NHOPI and Asian patients in Hawaii.



Epidemiological Characteristics of Cardiac Amyloidosis among Hawaii’s Majority-Minority Population PB96 (#442)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.